Significance of incidental focal uptake in prostate on 18-fluoro-2- deoxyglucose positron emission tomography CT images

British Journal of Radiology

Volumn 83, Issue 995, 2010, Pages 915-920

  Han, E J ^a   O, J H ^a   Choi, W H ^a   Yoo, Ie Ryung ^a   Chung, S K ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FOLLOW UP; HUMAN; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY;

ADULT; AGED; AGED, 80 AND OVER; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENTAL FINDINGS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78049322019     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/19887771     Document Type: Article

References (37)

1. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/ CT: current applications and future directions. Radiology 2006;238:405-22.
2. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 2007;11: iii-iv, xi-267.
3. Yap JT, Carney JP, Hall NC, Townsend DW. Image-guided cancer therapy using PET/CT. Cancer J 2004;10:221-33.
4. Lee JW, Kang KW, Paeng JC, Lee SM, Jang SJ, Chung JK, et al. Cancer screening using (18)F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report. Ann Nucl Med 2009;23:685-91.
5. Minamimoto R, Senda M, Uno K, Jinnouchi S, Iinuma T, Ito K, et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med 2007;21:481-98.
6. Wang X, Koch S. Positron emission tomography/computed tomography potential pitfalls and artifacts. Curr Probl Diagn Radiol 2009;38:156-69.
7. Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005;46:752-7. (Pubitemid 43750749)
8. Even-Sapir E, Lerman H, Gutman M, Lievshitz G, Zuriel L, Polliack A, et al. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 2006;33:541-52.
9. Choi JY, Lee KS, Kwon OJ, Shim YM, Baek CH, Park K, et al. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol 2005;23:7654-9. (Pubitemid 46291830)
10. Kojima S, Zhou B, Teramukai S, Hara A, Kosaka N, Matsuo Y, et al. Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: the Nishidai clinic study. Eur J Cancer 2007;43:1842-8. (Pubitemid 47238247)
11. Terauchi T, Murano T, Daisaki H, Kanou D, Shoda H, Kakinuma R, et al. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report. Ann Nucl Med 2008;22:379-85. (Pubitemid 351938513)
12. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009;53:171-84.
13. Fuchsjager M, Shukla-Dave A, Akin O, Barentsz J, Hricak H. Prostate cancer imaging. Acta Radiol 2008;49:107-20.
14. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243:28-53. (Pubitemid 46579693)
15. TakahashiN, Inoue T, Lee J, Yamaguchi T, Shizukuishi K. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology 2007;72:226-33. (Pubitemid 351161615)
16. Bouchelouche K, Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol 2008;179:34-45. (Pubitemid 350225698)
17. Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 2007;51:1511-20; discussion 1520-1. (Pubitemid 46634756)
18. von Mallek D, Backhaus B, Muller SC, Matthies A, Palmedo H, Jaeger U, et al. Technical limits of PET/CT with 18FDG in prostate cancer. Aktuelle Urol 2006;37:218-21.
19. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001;57:108-11.
20. Liu Y. FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate. World J Surg Oncol 2008; 6:64.
21. Ho L, Quan V, Henderson R, Seto J. High-grade urothelial carcinoma of the prostate on FDG PET-CT. Clin Nucl Med 2007;32:746-7.
22. Kao PF, Chou YH, Lai CW. Diffuse FDG uptake in acute prostatitis. Clin Nucl Med 2008;33:308-10.
23. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 1996;155:994-8.
24. Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrun A. Positron emission tomography in urological oncology. J Urol 1998;159:347-56.
25. Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Positron emission tomography and molecular imaging of the prostate: an update. BJU Int 2006;97:923-31.
26. Oyama N, Akino H, Kanamaru H, Okada K. Fluorodeoxyglucose positron emission tomography in diagnosis of untreated prostate cancer. Nippon Rinsho 1998; 56:2052-5.
27. Reynolds MA, Kastury K, Groskopf J, Schalken JA, Rittenhouse H. Molecular markers for prostate cancer. Cancer Lett 2007;249:5-13.
28. McNeal JE. The zonal anatomy of the prostate. Prostate 1981;2:35-49.
29. Muezzinoglu B, Gurbuz Y. Stromal microcalcification in prostate. Malays J Pathol 2001;23:31-3.
30. Bock E, Calugi V, Stolfi V, Rossi P, D'Ascenzo R, Solivetti FM. Calcifications of the prostate: a transrectal echographic study. Radiol Med 1989;77:501-3.
31. Shoskes DA, Lee CT, Murphy D, Kefer J, Wood HM. Incidence and significance of prostatic stones in men with chronic prostatitis/chronic pelvic pain syndrome. Urology 2007;70:235-8. (Pubitemid 47362267)
32. Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004;63:709-15.
33. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 2005;40:121-8.
34. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36:31-5.
35. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126-31.
36. Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, et al. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials 2009;30: 81-7.
37. Jereczek-Fossa BA, Curigliano G, Orecchia R. Systemic therapies for non-metastatic prostate cancer: review of the literature. Onkologie 2009;32:359-63.